Denosumab biosimilar (Zhejiang Hisun)

地舒单抗生物类似药（海正药业）

Report date: 2025/06/05 11:45:43

Base Information

Drug NameDenosumab biosimilar (Zhejiang Hisun)
Drug Alias NameRecombinant human anti-RANKL antibody (Hisun Pharma)重组抗RANKL全人源单抗（海正药业）HS629
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanBiologics > Biosimilar
Mechanisms of ActionTumor necrosis factor ligand superfamily member 11 inhibitors
TargetsTumor necrosis factor ligand superfamily member 11
Therapy Area/IndicationsBone metastasesSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesZhejiang Hisun Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesZhejiang Hisun Pharmaceutical Co LtdHisun Pharmaceutical (Hangzhou) Co Ltd
Inactive CompaniesN/A
Active IndicationsBone metastasesSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A